Testosterone Enanthate Geriatric (65+): Transition to Adult Care

What Does "Transition to Adult Care" Mean for a 65+ Patient on Testosterone Enanthate?

The phrase "transition to adult care" in geriatric testosterone therapy covers two overlapping situations. First, an older man may be transferring from a pediatric or young-adult endocrinologist who managed his hypogonadism for decades, arriving at a new geriatric-focused provider with an established injection regimen. Second, a man over 65 may be starting testosterone enanthate for the first time, moving from watchful waiting into active pharmacologic treatment. Both situations require the same evidence-based framework.

Why Geriatric Patients Are Not Simply "Older Adults"

Physiologic changes in men over 65 alter how testosterone enanthate is absorbed, distributed, and metabolized. Serum sex hormone-binding globulin (SHBG) rises with age, reducing free testosterone even when total testosterone appears adequate. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that free testosterone declines faster than total testosterone after age 60, making free T measurement a useful adjunct in this population.

Body composition also shifts. Older men carry more adipose tissue relative to lean mass, which increases aromatase activity and estradiol conversion. Renal and hepatic clearance slow, meaning the half-life of testosterone enanthate's active ester may extend modestly, which supports lower starting doses.

The Endocrine Society Position on Older Men

The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism states: "We suggest that clinicians consider initiating testosterone therapy in older men with consistently low testosterone concentrations and symptoms, after explicit discussion of uncertain benefits and risks." Academic.oup.com/jcem. This language reflects genuine equipoise, not a recommendation against treatment.

Confirming Hypogonadism Before Starting or Continuing Therapy

Two separate morning fasting serum total testosterone measurements below 300 ng/dL are required before initiating or re-confirming hypogonadism. The FDA-approved labeling for testosterone enanthate specifies that the diagnosis must be confirmed by laboratory testing.

LH and FSH Help Classify the Cause

Measuring luteinizing hormone (LH) and follicle-stimulating hormone (FSH) alongside testosterone distinguishes primary hypogonadism (high LH/FSH, testicular origin) from secondary hypogonadism (low or normal LH/FSH, hypothalamic-pituitary origin). Secondary hypogonadism in older men frequently reflects age-related changes in GnRH pulse amplitude rather than structural pituitary disease, but an MRI is indicated if prolactin is elevated above 20 ng/mL or total testosterone is below 150 ng/dL.

Free Testosterone in Equivocal Cases

When total testosterone falls in the 300 to 400 ng/dL range but symptoms are present, calculated free testosterone below 65 pg/mL may support a treatment decision. The Endocrine Society guideline identifies free testosterone as a secondary diagnostic measure for equivocal cases.

Dosing Testosterone Enanthate in Men Over 65

Starting doses for geriatric patients should be conservative. The standard adult dosing range of 100 to 200 mg intramuscularly every 1 to 2 weeks produces peak testosterone concentrations that may exceed 1,500 ng/dL in older men with reduced clearance. Peaks above 1,500 ng/dL correlate with erythrocytosis risk, a concern amplified in patients with baseline hematocrit above 48%.

Recommended Starting Protocol

A reasonable geriatric starting protocol is testosterone enanthate 50 to 75 mg intramuscularly every 7 to 10 days. This shorter interval at a lower dose flattens the peak-to-trough fluctuation that IM long-acting esters create. A 2010 pharmacokinetic study in Clinical Pharmacokinetics demonstrated that dividing the same total monthly dose into more frequent smaller injections significantly reduces supratherapeutic peak concentrations.

Patients already stable on a higher dose from a prior provider may stay on that dose if their trough total testosterone is in the 400 to 600 ng/dL range, hematocrit is below 50%, and cardiovascular risk is documented as low or managed.

Titration Schedule

• Week 0: baseline labs, first 50 to 75 mg dose
• Week 6 to 8: trough total T, hematocrit, PSA, blood pressure
• Week 12 to 16: dose adjustment if trough T is below 350 ng/dL or above 600 ng/dL
• Month 6: full metabolic panel, bone turnover markers if DEXA not yet obtained
• Month 12: comprehensive reassessment including cardiovascular review

Dose increases beyond 100 mg per injection are generally not appropriate in men over 65 without specialist consultation, given the cardiovascular and hematologic risk profile documented in the Testosterone Trials (TTrials), which enrolled 790 men aged 65 and older.

Cardiovascular Risk Assessment: The Non-Negotiable First Step

Cardiovascular risk is the most contentious safety domain in geriatric testosterone therapy. The TTrials cardiovascular substudy found a significantly higher rate of coronary artery non-calcified plaque volume in testosterone-treated men vs. Placebo after 12 months: an increase of 41% vs. 27% (P<0.001) in the testosterone arm vs. Placebo arm of the imaging sub-study NEJM 2017. The clinical significance of this finding remains debated, but it supports caution.

Conditions Requiring Pause or Specialist Consultation

Testosterone enanthate should not be initiated within 6 months of a myocardial infarction or stroke. Active or recent heart failure with ejection fraction below 40%, uncontrolled hypertension (systolic above 160 mmHg), or a known inherited thrombophilia each require specialist sign-off before any injection. The American Heart Association's 2023 scientific statement on androgens and cardiovascular disease calls for individualized risk stratification rather than blanket prohibition.

Blood Pressure Targets Before Starting

Systolic blood pressure should be below 140 mmHg before the first injection. Testosterone can cause mild sodium and water retention, raising blood pressure by 2 to 5 mmHg. In a patient already at 145/90 mmHg, that increment matters clinically. Document blood pressure at every injection visit.

Hematologic Monitoring: Erythrocytosis Is the Most Common Adverse Event

Erythrocytosis, defined as hematocrit above 54%, is the most frequent adverse event in older men on testosterone therapy. The Endocrine Society 2018 guideline states: "We recommend checking hematocrit at baseline, at 3 to 6 months, and then annually. If the hematocrit exceeds 54%, stop therapy until hematocrit decreases to a safe level." Academic.oup.com/jcem.

Why Older Men Are at Higher Risk

Baseline erythropoietin sensitivity may already be elevated in men over 65, particularly those with obstructive sleep apnea (OSA). OSA prevalence rises sharply after age 60, and undiagnosed OSA combined with exogenous testosterone roughly doubles erythrocytosis risk. A 2017 review in CHEST found that 40 to 60% of men on testosterone therapy had undiagnosed OSA at baseline.

Screening with the STOP-BANG questionnaire takes under two minutes at intake and can flag patients who need polysomnography before injection one.

Management of Elevated Hematocrit

If hematocrit reaches 52 to 54%, reduce the dose by 25% and re-check in 6 weeks. Above 54%: hold therapy, investigate secondary causes (OSA, myeloproliferative disease), and do not restart until hematocrit drops below 50%. Therapeutic phlebotomy is an option for patients who clearly benefit from testosterone but develop recurrent erythrocytosis, though FDA labeling does not endorse phlebotomy as a substitute for dose reduction.

Prostate Safety Monitoring

Testosterone does not cause prostate cancer de novo, but it may stimulate pre-existing androgen-sensitive disease. The 2018 Endocrine Society guideline recommends withholding testosterone therapy in men with a PSA above 4.0 ng/mL or palpable prostate abnormality until urology evaluation is complete.

PSA Monitoring Schedule

• Baseline PSA before first injection
• PSA at 3 months (captures early stimulation of occult disease)
• Annual PSA thereafter if stable
• Urology referral if PSA rises more than 1.4 ng/mL above baseline within 12 months, or if any single reading exceeds 4.0 ng/mL

A 2004 meta-analysis in JAMA covering 19 randomized controlled trials found no statistically significant increase in prostate cancer diagnoses with testosterone therapy compared to placebo, though follow-up durations were generally short (under 3 years).

Digital Rectal Exam

Digital rectal exam (DRE) at baseline and annually is reasonable in men 65 and older, though the USPSTF 2018 prostate cancer screening recommendation does not mandate DRE as a standalone screening tool. The value in testosterone therapy patients is identifying palpable nodules that PSA alone may miss.

Bone Mineral Density: An Underused Benefit Endpoint

Men with hypogonadism have lower bone mineral density (BMD) at baseline. After 65, vertebral fracture risk rises steeply. The TTrials bone substudy found that testosterone therapy in men 65 and older significantly increased BMD at the lumbar spine by 7.5% at 12 months compared to 0.8% in the placebo group (P<0.001) NEJM 2017 TTrials bone results.

A baseline DEXA scan documents starting BMD and helps justify therapy continuation if cardiovascular concerns arise. Repeat DEXA at 24 months. Calcium 1,000 to 1,200 mg/day and vitamin D 800 to 1,000 IU/day should accompany testosterone therapy in men 65 and older per National Osteoporosis Foundation guidance.

Cognitive and Functional Outcomes: What the Data Actually Show

The TTrials cognitive substudy enrolled 493 older men and found no statistically significant improvement in cognitive function after 12 months of testosterone therapy compared to placebo JAMA Internal Medicine 2017. Physical function improved modestly in the physical function substudy, with the testosterone group walking 32 more meters on a 6-minute walk test vs. Placebo.

Frailty Screening Before Starting

Frailty, defined by Fried criteria (weight loss, exhaustion, low grip strength, slow gait speed, low activity), is present in 7 to 12% of community-dwelling men over 65. Frail older men were underrepresented in TTrials. Testosterone therapy may theoretically worsen fluid retention and erythrocytosis in frail patients, and a geriatrician co-consult is advisable for men meeting two or more Fried frailty criteria. A 2019 systematic review in JAMA Network Open found that testosterone therapy modestly improved lean mass and grip strength in older men, but effects on mobility and functional independence remained inconsistent across trials.

Managing Patients Transferred from a Prior Provider

Verifying the Previous Regimen

When a 65+ patient transfers with an established testosterone enanthate prescription, obtain:

• The prior injection dose, frequency, and route
• Most recent trough total testosterone (within 90 days, ideally)
• Most recent hematocrit and PSA
• Documentation of cardiovascular risk assessment
• Any prior adverse events or dose holds

If any of these records are missing, treat the patient as a new initiation and repeat baseline labs before continuing injections.

Dose Continuity vs. Dose Adjustment

A patient stable on 100 mg IM every 2 weeks with a trough of 420 ng/dL, hematocrit of 44%, PSA of 1.8 ng/mL, and no cardiovascular events may continue that regimen with standard geriatric monitoring. A patient transferred on 200 mg every 2 weeks with a trough of 820 ng/dL should have a dose reduction conversation before the next injection. Supratherapeutic troughs in older men are not a therapeutic target and introduce unnecessary risk.

Documenting Consent and Goals of Care

Geriatric patients sometimes have conflicting goals of care, such as wanting testosterone for energy while also being managed for polycythemia vera or recent pulmonary embolism. Each prescription renewal in this age group should include a brief structured note documenting the patient's primary symptom goals, acceptable risk tolerance, and any new comorbidities since the last visit.

Drug Interactions Common in the 65+ Population

Older men are frequently on multiple medications. Testosterone enanthate has clinically significant interactions with several drug classes common in this age group.

• Warfarin: Testosterone may increase warfarin sensitivity, raising INR. Check INR within 1 week of starting or changing testosterone dose. A 1990 case series in BMJ documented INR increases of 0.5 to 2.0 points after testosterone initiation in anticoagulated patients.
• Insulin and oral hypoglycemics: Testosterone improves insulin sensitivity. Men with type 2 diabetes may need hypoglycemic dose reductions within the first 4 to 8 weeks of therapy. The TTrials cardiometabolic substudy found a reduction in insulin resistance markers at 12 months.
• Corticosteroids: Concurrent use may increase fluid retention and blood pressure.
• Opioids: Chronic opioid use suppresses LH and FSH, causing secondary hypogonadism. Initiating testosterone enanthate while managing opioid-induced hypogonadism is appropriate, but opioid dose reduction remains the primary intervention where possible.

Injection Technique and Administration for Older Patients

Site Selection and Needle Gauge

Testosterone enanthate is administered by deep intramuscular injection. The preferred sites are the vastus lateralis (lateral thigh) or the gluteus medius. In older men with reduced muscle mass, the deltoid is not appropriate for volumes above 1 mL. Use a 1 to 1.5 inch, 21 to 23 gauge needle. Older men with sarcopenia may require a 1.5 inch needle to reliably reach muscle tissue.

Self-Injection Education

Self-injection is appropriate for cognitively intact older adults with adequate dexterity. Provide a structured training session. A 2021 survey published in Andrology found that 82% of men who received structured injection training reported high confidence in self-administration at 3 months. For men with arthritis or tremor, caregiver-administered or clinic-administered injections are more appropriate.

When to Discontinue Testosterone Enanthate in Older Men

Discontinuation is appropriate if any of the following occur:

• Hematocrit exceeds 54% twice despite dose reduction
• New diagnosis of prostate cancer (androgen-sensitive histology)
• Acute cardiovascular event (MI, stroke, DVT/PE) within the preceding 6 months
• PSA rises more than 1.4 ng/mL from baseline within 12 months without urologic explanation
• Patient no longer desires therapy or reports no symptomatic benefit at 6 months

After discontinuation, serum testosterone typically returns to baseline within 4 to 6 weeks for enanthate given its approximately 4.5-day half-life. Hypogonadal symptoms may recur. Counsel patients that discontinuation is a reversible decision and restart can be considered once the precipitating concern resolves.